- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07520006
Estudio de NX-5948 en combinación con otros agentes en adultos con neoplasias malignas de células B
Un estudio abierto, multicéntrico, de fase 1b/2 para evaluar la seguridad y eficacia de NX-5948 en combinación con otros agentes en adultos con neoplasias malignas de células B
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Bexobrutideg is an investigational drug designed to target a protein called Bruton tyrosine kinase (BTK), which helps cancer cells grow in certain blood cancers like CLL and SLL. Bexobrutideg is a protein degrader, which means it finds and destroys the BTK in the cell. Venetoclax, rituximab, and obinutuzumab are approved medications that are used to treat CLL/SLL.
The study will look at:
- How safe bexobrutideg is for patients with CLL or SLL when taken with these other treatments
- The effects of bexobrutideg in the body when taken with these other treatments
- How well bexobrutideg treats CLL or SLL when taken with these other treatments
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Additional Site Contact Information
- Número de teléfono: 415-417-3418
- Correo electrónico: clinicaltrials@nurixtx.com
Ubicaciones de estudio
-
-
California
-
Irvine, California, Estados Unidos, 92618
- Aún no reclutando
- City of Hope Orange County Lennar Foundation Cancer Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80012
- Reclutamiento
- Rocky Mountain Cancer Centers
-
-
Florida
-
Coral Gables, Florida, Estados Unidos, 33146
- Aún no reclutando
- University of Miami
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Aún no reclutando
- University of Kansas Cancer Center
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89169
- Aún no reclutando
- Comprehensive Cancer Centers of Nevada
-
-
New Jersey
-
Belleville, New Jersey, Estados Unidos, 07109
- Aún no reclutando
- New Jersey Cancer Care
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401
- Reclutamiento
- Oncology Associates of Oregon
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- Reclutamiento
- UPMC Hillman Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- SCRI Oncology Partners
-
-
Texas
-
Tyler, Texas, Estados Unidos, 75702
- Reclutamiento
- Texas Oncology - Northeast
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Adequate organ and bone marrow function
- Measurable disease by computed tomography (CT) per iwCLL
- For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)
- For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria
- Must sign an informed consent form indicating understanding of the study purpose and procedures and willingness to participate
Key Exclusion Criteria:
- Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
- Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
- Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation
- Use of systemic corticosteroids (>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast
- Previously treated with a BTK degrader
- Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment
- Known central nervous system (CNS) lymphoma or leukemia
- Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
- Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment
Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: NX-5948 + venetoclax
|
Administered orally once daily as a capsule
Otros nombres:
Administered orally once daily as a tablet per prescribing information |
|
Experimental: NX-5948 + venetoclax + rituximab
|
Administered orally once daily as a capsule
Otros nombres:
Administered orally once daily as a tablet per prescribing information Administered as an intravenous (IV) infusion per prescribing information |
|
Experimental: NX-5948 + venetoclax + obinutuzumab
|
Administered orally once daily as a capsule
Otros nombres:
Administered orally once daily as a tablet per prescribing information Administered as an IV infusion per prescribing information |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Número de participantes con eventos adversos emergentes del tratamiento
Periodo de tiempo: Hasta aproximadamente 7 años
|
Hasta aproximadamente 7 años
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective response rate as determined by investigator
Periodo de tiempo: Up to approximately 7 years
|
The percentage of participants with response as determined according to 2018 iwCLL guidelines; response includes complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR), PR with lymphocytosis (PR-L), and nodular PR |
Up to approximately 7 years
|
|
Duration of response as determined by investigator
Periodo de tiempo: Up to approximately 7 years
|
Time from the date of the first response to the date of documented progressive disease or death due to any cause, whichever is earlier |
Up to approximately 7 years
|
|
Progression-free survival as determined by investigator
Periodo de tiempo: Up to approximately 7 years
|
Time from the date of the first dose of study drug to the date of documented progressive disease or death due to any cause, whichever is earlier |
Up to approximately 7 years
|
|
Complete response rate as determined by investigator
Periodo de tiempo: Up to approximately 7 years
|
The percentage of participants with CR or CRi as determined according to 2018 iwCLL guidelines; includes CR + CRi for participants with CLL. |
Up to approximately 7 years
|
|
Time to response as determined by investigator
Periodo de tiempo: Up to approximately 7 years
|
Time from the start date of study treatment to the date of the first assessment of a response |
Up to approximately 7 years
|
|
Overall survival
Periodo de tiempo: Up to approximately 7 years
|
Time from the start date of study treatment to the date of death from any cause |
Up to approximately 7 years
|
|
Pharmacokinetic profile of NX-5948
Periodo de tiempo: Up to approximately 1 year
|
NX-5948 concentrations in blood samples |
Up to approximately 1 year
|
|
Pharmacokinetic profile of venetoclax
Periodo de tiempo: Up to approximately 1 year
|
Venetoclax concentrations in blood samples |
Up to approximately 1 year
|
|
Change from baseline in Global Health Status/Quality of Life on the European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30)
Periodo de tiempo: Baseline and up to approximately 27 months
|
Percentage of participants with a clinically meaningful change from baseline using the EORTC QLQ-C30 questionnaire to assess the overall quality of life |
Baseline and up to approximately 27 months
|
|
Change from baseline in European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)
Periodo de tiempo: Baseline and up to approximately 27 months
|
Percentage of participants with a clinically meaningful change from baseline using the EQ-5D-5L questionnaire to assess health outcomes |
Baseline and up to approximately 27 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Study Director, Nurix Therapeutics, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias
- Enfermedad crónica
- Atributos de la enfermedad
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Leucemia de células B
- Linfoma
- Leucemia Linfoide
- Leucemia
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades hemic y linfáticas
- Linfoma de células B
- Leucemia Linfocítica Crónica De Células B
- Aminoácidos, péptidos y proteínas
- Proteínas
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Anticuerpos, monoclonales, derivados de murino
- Rituximab
- venetoclax
- obinutuzumab
Otros números de identificación del estudio
- NX-5948-203
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .